What is Cagrilintide? An amylin analog research overview

Cagrilintide is a long-acting analog of amylin — a peptide hormone co-secreted with insulin by pancreatic beta cells. Where GLP-1 receptor agonists like semaglutide have dominated obesity and glycemic research over the past decade, amylin analogs represent a distinct and complementary pharmacological pathway. Cagrilintide has become the most-studied amylin analog in this space, largely because of its role in the CagriSema combination with semaglutide.

This post is an introduction to what cagrilintide is, how its mechanism differs from GLP-1 receptor agonists, and where it sits in the current peptide research landscape.

The amylin pathway

Amylin (islet amyloid polypeptide, IAPP) is a 37-residue peptide released alongside insulin in response to meals. It slows gastric emptying, suppresses glucagon secretion, and acts centrally on the area postrema to promote satiety. Native amylin is unsuitable as a research or therapeutic agent because it readily aggregates into amyloid fibrils — a chemistry problem that also underlies its role in type 2 diabetes pathology.

Pramlintide, an earlier amylin analog approved in 2005, addresses aggregation by substituting three residues (positions 25, 28, 29) with proline. Pramlintide’s half-life, however, is short (approximately 48 minutes), requiring pre-meal dosing.

Cagrilintide takes the pharmacology further. Its structure is optimized for both aggregation resistance and a long plasma half-life — around 180 hours in humans — allowing once-weekly administration. That half-life extension is achieved through a fatty acid side chain that binds circulating albumin, a strategy Novo Nordisk has used across its GLP-1 and amylin programs.

Receptor pharmacology

Amylin’s actions are mediated through the amylin receptors — heterodimeric complexes formed when the calcitonin receptor (CTR) associates with one of three receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3). The resulting complexes are labeled AMY1, AMY2, and AMY3.

Cagrilintide is a non-selective agonist at all three amylin receptor subtypes. It also retains meaningful affinity at the calcitonin receptor itself, which some research suggests may contribute to its metabolic effects. This receptor promiscuity is a key mechanistic distinction from GLP-1 receptor agonists, which act through a single, distinct G-protein-coupled receptor.

Where cagrilintide differs from GLP-1s

The GLP-1 receptor and the amylin receptor complexes are pharmacologically distinct, but their downstream effects on food intake and body weight regulation overlap. This overlap is what makes combination therapy interesting.

Central appetite suppression: both pathways signal through hindbrain regions that regulate satiety, but through different receptor populations. Combined stimulation appears to produce greater cumulative appetite reduction than either alone.
Gastric emptying: amylin analogs and GLP-1 receptor agonists both slow gastric emptying, though through partially distinct mechanisms.
Glucagon suppression: amylin analogs suppress postprandial glucagon; GLP-1 receptor agonists similarly suppress glucagon in a glucose-dependent manner.
Insulin sensitivity: effects here differ. GLP-1 receptor agonists have well-characterized effects on insulin secretion; amylin analogs act more on satiety and gastric motility than on insulin secretion directly.

CagriSema and combination research

CagriSema is a fixed-ratio combination of cagrilintide and semaglutide. Phase 2 clinical research has explored whether the two agents produce additive or synergistic effects on body weight. Published results have generally shown weight reductions greater than semaglutide monotherapy at matched semaglutide doses, though the phase 3 program (REDEFINE) will provide the definitive picture on the magnitude of the additive effect.

For research use, cagrilintide and semaglutide are studied both separately and in combination. Analytical characterization of cagrilintide typically uses HPLC with mass spectrometric confirmation; the fatty acid side chain and modified residue positions produce a distinctive mass signature.

Storage and handling considerations

Cagrilintide is supplied lyophilized. Its stability profile is broadly comparable to other albumin-binding modified peptides — the fatty acid side chain and the aggregation-resistant residue substitutions both improve chemical stability relative to native amylin. Reconstituted stock is typically stored at 2-8°C for short-term working use and at -20°C or below for longer-term storage of the lyophilized material.

The chemistry of storage — deamidation, oxidation of methionine, aggregation kinetics — follows the same general framework as other research peptides. Our storage temperature stability post covers the underlying mechanisms.

Current research landscape

Cagrilintide sits in a broader wave of next-generation obesity and metabolic research peptides. The GLP-1 research landscape post covers the wider field. Key context for cagrilintide specifically:

Amylin analogs are now considered a distinct pillar of obesity pharmacology, alongside GLP-1 receptor agonists and multi-agonist peptides like tirzepatide and retatrutide.
Amycretin, a single-molecule GLP-1/amylin dual agonist also in development at Novo Nordisk, represents an even more integrated approach.
The combination strategy (CagriSema) versus the single-molecule strategy (amycretin) is one of the more interesting open pharmacological questions in the field.

Analytical verification

For any research use of cagrilintide, the same analytical rigor applies as with other modified peptides. A legitimate certificate of analysis will report HPLC purity (typically ≥98% for research-grade material), mass verification by MS, water content, and endotoxin. The reading a COA post walks through how to interpret each of these values.

The fatty acid side chain in cagrilintide produces a characteristic mass shift versus the base amylin analog — legitimate MS reports will confirm this.